# Inmune Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Inmune Bio, Inc.). ## Overview Inmune Bio, Inc. is a clinical-stage biotechnology company developing immunology-based therapies for inflammatory, neurodegenerative, and rare disease indications. Its pipeline includes CORDStrom and XPro, with the company still pre-commercial and dependent on clinical progress, regulatory milestones, and external financing. ## Products & services • CORDStrom cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) • XPro, an anti-TNF biologic program for neuroinflammation • Preclinical and clinical development services for pipeline candidates • Regulatory and CMC development activities for FDA/EMA/MHRA submissions - **CORDStrom** (60%) — Cell therapy program focused on RDEB and related rare disease treatment pathways. - **XPro** (25%) — Anti-inflammatory biologic program aimed at neuroinflammation and CNS-related disorders. - **Collaborations and licensing** (10%) — Revenue from license agreements, data access arrangements, and related milestones. - **Other research programs** (5%) — Earlier-stage discovery and preclinical work supporting future pipeline expansion. - CORDStrom cell therapy for RDEB and related rare pediatric disease use - XPro biologic program targeting neuroinflammation and immune signaling - Clinical trial execution and translational development for product candidates - CMC, regulatory filing, and manufacturing development support - License-based access to external clinical data, such as Mission EB ## Customers The company does not sell broadly to end consumers; its economic customers are patients, physicians, hospitals, and regulators that determine whether its therapies can be adopted and reimbursed. In the near term, value is created through clinical trial enrollment, licensing arrangements, and potential future commercialization of approved biologic products. Academic and hospital partners also matter because they generate clinical data and support development milestones. - **Rare disease patients and caregivers** (primary) — Patients with RDEB and other severe unmet-need conditions who would use CORDStrom if approved. - **Clinical investigators and hospitals** (primary) — Trial sites that enroll patients, administer study treatment, and generate efficacy/safety data. - **Regulatory agencies** (primary) — FDA, EMA, and MHRA review the company’s CMC, safety, and efficacy packages and determine approval. - **Strategic partners and licensors** (secondary) — Third parties that may fund, license, or commercialize programs or provide clinical data access. - Patients with rare and severe inflammatory or genetic diseases - Hospitals and clinical investigators running the company’s trials - Regulators such as the FDA, EMA, and MHRA - Potential licensing or strategic partners for data and commercialization - Physicians seeking treatment options where standard care is limited ## Geography Inmune Bio is headquartered in the United States, but a meaningful part of its research and development spending occurs in Australia and the United Kingdom. The company also references interactions with U.S., U.K., and European regulators, reflecting a development footprint that is broader than its current revenue base. Foreign currency exposure matters because operating costs are incurred in pounds sterling and Australian dollars while reporting in U.S. dollars. - United States is the corporate and reporting base - R&D spending is significant in the United Kingdom and Australia - Regulatory work spans the FDA, EMA, and MHRA - Foreign currency swings affect UK and Australia operating costs - Current revenue is minimal and not geographically diversified ## Strategy The company’s strategy is to advance its lead programs through clinical development, secure regulatory designations, and convert trial data into approval and commercialization opportunities. It is also using collaborations, licensing, and capital raises to fund operations while it remains pre-revenue and cash-consuming. The Mission EB data license and FDA orphan/rare pediatric designations show a focus on de-risking CORDStrom and improving its partnering and approval profile. - **Advance CORDStrom toward marketing authorization** (short-term) — Approval would unlock commercialization, exclusivity benefits, and potential PRV value. - **Use external clinical data and partnerships** (short-term) — Licensing and collaborations can accelerate development and reduce internal spend. - **Fund operations through equity and strategic financing** (short-term) — The company has recurring losses and substantial doubt about going concern. - **Build clinical evidence for XPro and other programs** (medium-term) — Pipeline breadth can create future value beyond a single asset. - Advance CORDStrom through FDA-facing development and approval steps - Use orphan and rare pediatric designations to improve regulatory economics - Progress XPro and other pipeline assets through clinical proof-of-concept - Leverage external data and collaborations to reduce development risk - Raise capital through equity and strategic sources to fund R&D ## Risks Inmune Bio faces classic clinical-stage biotech risks: trial failure, regulatory delay, and uncertainty around whether its programs can reach approval and commercialization. The company also has a going-concern profile, with recurring losses and dependence on equity financing, while foreign-currency exposure and third-party manufacturing/CRO reliance can add volatility to costs and execution. - **Going concern and liquidity shortfall** [critical] — The company has recurring net losses and negative cash flows and may need additional capital before commercialization. - **Clinical development failure** [high] — Pipeline value depends on positive trial outcomes for CORDStrom and XPro. - **Regulatory and CMC execution risk** [high] — FDA/EMA/MHRA feedback can require additional studies, manufacturing changes, or delays. - **Foreign exchange volatility** [medium] — R&D is incurred in Australia and the United Kingdom, creating translation and transaction exposure. - Going-concern risk due to recurring losses and negative operating cash flow - Clinical trial risk if CORDStrom or XPro fail to show sufficient efficacy or safety - Regulatory risk from FDA, EMA, or MHRA feedback delaying approval - Financing risk because operations depend on equity and external capital - FX risk from UK and Australia R&D spending denominated in local currencies ## Accounting The most important accounting issue is revenue recognition, because reported revenue has been small and tied to a terminated license agreement and prior asset sales rather than product sales. Investors should also watch impairment and estimate risk in acquired in-process R&D, stock-based compensation, and foreign-currency translation, all of which can materially affect reported losses for a pre-commercial biotech. - **Revenue recognition on license agreements** — Can create lumpy quarterly revenue and comparability issues - **Impairment of acquired in-process R&D** — Non-cash charge can materially widen reported losses - **Stock-based compensation** — Raises operating expenses and affects loss metrics - **Foreign currency translation** — Moves expenses, assets, and liabilities in reported U.S. dollars - Revenue is driven by license timing and one-off transactions, not product sales - Impairment of acquired in-process R&D can create large non-cash charges - Stock-based compensation is a meaningful operating expense for a small biotech - Foreign-currency translation affects UK and Australia balances and expenses - Going-concern disclosures reflect management judgment on liquidity and runway --- *Last updated: 2026-04-28T20:17:29.237342+00:00*